Fixed Duration Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone Quadruplet for Newly Diagnosed Multiple Myeloma - MRD Negativity and Survival Outcomes
Year: 2022
Type: article
Study design: Clinical Trial
Source: Blood
Authors: Shaji K Kumar, Betsy Laplant, Erik J Asmus, Francis K. Buadi, Wilson I. Gonsalves, Eli Muchtar, David Dingli, Melanie Ann Thompson, Ronald Go, Rahma M Warsame, Taxiarchis Kourelis, Yi L. Hwa, Amie Fonder, Miriam A. Hobbs, Martha Q. Lacy, Angela Dispenzieri, Suzanne R. Hayman, Nelson Leung, Moritz Binder, S. Vincent Rajkumar, Morie A Gertz, Prashant Kapoor
Institution: Mayo Clinic
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4310108193